Robyn Karnauskas
Stock Analyst at Truist Securities
(2.35)
# 2,493
Out of 4,711 analysts
179
Total ratings
40%
Success rate
-0.15%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robyn Karnauskas
Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
---|---|---|---|---|---|---|---|
MRK Merck & Co. | Maintains: Buy | $132 → $130 | $98.05 | +32.59% | 10 | Nov 7, 2024 | |
AMGN Amgen | Downgrades: Hold | $320 → $333 | $263.38 | +26.43% | 11 | Oct 14, 2024 | |
GILD Gilead Sciences | Maintains: Hold | $82 → $83 | $92.57 | -10.34% | 18 | Aug 15, 2024 | |
ABBV AbbVie | Reiterates: Buy | $195 → $210 | $175.58 | +19.60% | 8 | Jul 26, 2024 | |
BMEA Biomea Fusion | Downgrades: Hold | n/a | $4.23 | - | 3 | Jun 11, 2024 | |
BIIB Biogen | Maintains: Buy | $340 | $146.47 | +132.13% | 17 | May 16, 2024 | |
CRIS Curis | Maintains: Buy | $26 | $3.08 | +744.16% | 2 | May 15, 2024 | |
CHRS Coherus BioSciences | Maintains: Buy | $8 → $7 | $1.52 | +360.53% | 13 | May 13, 2024 | |
REGN Regeneron Pharmaceuticals | Maintains: Buy | $1,135 | $701.85 | +61.72% | 16 | Apr 3, 2024 | |
OABI OmniAb | Maintains: Buy | $10 | $3.50 | +185.71% | 2 | Mar 26, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 | $2.99 | +201.00% | 4 | Mar 26, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $74 | $20.65 | +258.35% | 2 | Mar 25, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 | $11.57 | +98.79% | 5 | Mar 25, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $48 | $25.86 | +85.61% | 5 | Mar 25, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $50 | $15.50 | +222.58% | 8 | Mar 25, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $850 | $767.76 | +10.71% | 4 | Mar 22, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $456 → $508 | $397.27 | +27.87% | 13 | Jan 31, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $36 | $26.36 | +36.57% | 5 | Dec 14, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $84 | $57.33 | +46.52% | 1 | Oct 6, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $25 | $46.24 | -45.93% | 1 | Oct 6, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $0.34 | - | 6 | Oct 5, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $140 | $65.66 | +113.22% | 5 | Sep 25, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $150 | $1.21 | +12,296.69% | 2 | Sep 6, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | $7 | $1.68 | +316.67% | 3 | Aug 16, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $55 | $16.98 | +223.91% | 1 | May 11, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $2.50 | - | 4 | Dec 6, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $29 | $2.85 | +917.54% | 1 | Nov 16, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $500 → $320 | $20.61 | +1,452.64% | 2 | Aug 23, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $15 | $8.65 | +73.41% | 5 | Aug 9, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $3.34 | +648.48% | 1 | Nov 11, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $85 | $0.88 | +9,557.99% | 1 | Oct 8, 2020 |
Merck & Co.
Nov 7, 2024
Maintains: Buy
Price Target: $132 → $130
Current: $98.05
Upside: +32.59%
Amgen
Oct 14, 2024
Downgrades: Hold
Price Target: $320 → $333
Current: $263.38
Upside: +26.43%
Gilead Sciences
Aug 15, 2024
Maintains: Hold
Price Target: $82 → $83
Current: $92.57
Upside: -10.34%
AbbVie
Jul 26, 2024
Reiterates: Buy
Price Target: $195 → $210
Current: $175.58
Upside: +19.60%
Biomea Fusion
Jun 11, 2024
Downgrades: Hold
Price Target: n/a
Current: $4.23
Upside: -
Biogen
May 16, 2024
Maintains: Buy
Price Target: $340
Current: $146.47
Upside: +132.13%
Curis
May 15, 2024
Maintains: Buy
Price Target: $26
Current: $3.08
Upside: +744.16%
Coherus BioSciences
May 13, 2024
Maintains: Buy
Price Target: $8 → $7
Current: $1.52
Upside: +360.53%
Regeneron Pharmaceuticals
Apr 3, 2024
Maintains: Buy
Price Target: $1,135
Current: $701.85
Upside: +61.72%
OmniAb
Mar 26, 2024
Maintains: Buy
Price Target: $10
Current: $3.50
Upside: +185.71%
Mar 26, 2024
Maintains: Buy
Price Target: $9
Current: $2.99
Upside: +201.00%
Mar 25, 2024
Reiterates: Buy
Price Target: $74
Current: $20.65
Upside: +258.35%
Mar 25, 2024
Reiterates: Buy
Price Target: $23
Current: $11.57
Upside: +98.79%
Mar 25, 2024
Reiterates: Buy
Price Target: $48
Current: $25.86
Upside: +85.61%
Mar 25, 2024
Reiterates: Buy
Price Target: $50
Current: $15.50
Upside: +222.58%
Mar 22, 2024
Reiterates: Buy
Price Target: $850
Current: $767.76
Upside: +10.71%
Jan 31, 2024
Maintains: Buy
Price Target: $456 → $508
Current: $397.27
Upside: +27.87%
Dec 14, 2023
Maintains: Buy
Price Target: $42 → $36
Current: $26.36
Upside: +36.57%
Oct 6, 2023
Reiterates: Buy
Price Target: $84
Current: $57.33
Upside: +46.52%
Oct 6, 2023
Downgrades: Hold
Price Target: $25
Current: $46.24
Upside: -45.93%
Oct 5, 2023
Downgrades: Hold
Price Target: n/a
Current: $0.34
Upside: -
Sep 25, 2023
Reiterates: Buy
Price Target: $140
Current: $65.66
Upside: +113.22%
Sep 6, 2023
Reiterates: Buy
Price Target: $150
Current: $1.21
Upside: +12,296.69%
Aug 16, 2023
Reiterates: Hold
Price Target: $7
Current: $1.68
Upside: +316.67%
May 11, 2023
Maintains: Buy
Price Target: $65 → $55
Current: $16.98
Upside: +223.91%
Dec 6, 2022
Downgrades: Hold
Price Target: n/a
Current: $2.50
Upside: -
Nov 16, 2022
Initiates: Buy
Price Target: $29
Current: $2.85
Upside: +917.54%
Aug 23, 2022
Maintains: Buy
Price Target: $500 → $320
Current: $20.61
Upside: +1,452.64%
Aug 9, 2022
Maintains: Buy
Price Target: $10 → $15
Current: $8.65
Upside: +73.41%
Nov 11, 2020
Initiates: Buy
Price Target: $25
Current: $3.34
Upside: +648.48%
Oct 8, 2020
Initiates: Buy
Price Target: $85
Current: $0.88
Upside: +9,557.99%